Merck & Co., Inc. : There is still some upside potential
Entry price | Target | Stop-loss | Potential |
---|
US$93.59 |
US$109 |
US$86 |
+16.47% |
---|
The current trading zone is interesting to the point that investors should pay attention to the stock and anticipate a return of the underlying upward trend.
Summary● The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Weaknesses● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● The company's enterprise value to sales, at 4.39 times its current sales, is high.
● The company appears highly valued given the size of its balance sheet.
● Over the past twelve months, analysts' consensus has been significantly revised downwards.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.